In vitro 3D microfluidic peritoneal metastatic colorectal cancer model for testing different oxaliplatin-based HIPEC regimens
Pleura and Peritoneum · 30.03.2024 · 9 (1) · 23-29
DOI: 10.1515/pp-2023-0033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pleura and Peritoneum, online erschienen am 28.02.2024. Verfasst von Aras Emre Canda und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Oncology, Dokuz Eylul University, Izmir, Türkiye. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dokuz Eylul University.
Abstract (Originalsprache)
Objectives
Treatment of colorectal peritoneal metastases with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) is still evolving. Conducting a randomized trial is challenging due to the high heterogeneity in the presentation of peritoneal disease and various surgical approaches. Biological research may facilitate more rapid translation of information into clinical practice. There is an emerging need for a preclinical model to improve HIPEC treatment protocols in terms of drug doses and treatment durations. The aim of the study is to design a tool that serves as an in vitro three-dimensional (3D) microfluidic peritoneal metastatic colorectal cancer model to test the efficacy of different HIPEC treatments.
Methods
We determined the effects of current therapy options using a 3D static disease model on human colon carcinoma cell lines (HCT 116) and transforming growth factor-β1 induced epithelial-to-mesenchymal transition (EMT) HCT 116 lines at 37 °C and 42 °C for 30, 60, and 120 min. We determined oxaliplatin’s half maximal inhibitory concentrations in a 3D static culture by using viability assay. Clinical practices of HIPEC were applied in the developed model.
Results
EMT-induced HCT 116 cells were less sensitive to oxaliplatin treatment compared to non-induced cells. We observed increased cytotoxicity when increasing the temperature from 37 °C to 42 °C and extending the treatment duration from 30 to 120 min. We found that 200 mg/m 2 oxaliplatin administered for 120 min is the most effective HIPEC treatment option within the framework of clinic applications.
Conclusions
The tool map provide insights into creating more realistic pre-clinical tools that could be used for a patient-based drug screening.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Oncology, Dokuz Eylul University, Izmir, Türkiye.
- Institute of Oncology, Department of Translational Oncology, Dokuz Eylul University, Izmir, Türkiye.
ORCID-Profile: Aras Emre Canda, Tolga Sever, Gizem Calibasi Kocal, Yasemin Basbinar, Hulya Ellidokuz
Förderung
- Dokuz Eylul University
Zitieren
APA
Canda, A. E., Sever, T., Calibasi Kocal, G., Basbinar, Y., & Ellidokuz, H. (2024). In vitro 3D microfluidic peritoneal metastatic colorectal cancer model for testing different oxaliplatin-based HIPEC regimens. Pleura and Peritoneum, 9(1), 23-29. https://doi.org/10.1515/pp-2023-0033
Vancouver
Canda AE, Sever T, Calibasi Kocal G, Basbinar Y, Ellidokuz H. In vitro 3D microfluidic peritoneal metastatic colorectal cancer model for testing different oxaliplatin-based HIPEC regimens. Pleura and Peritoneum. 2024;9(1):23-29. doi:10.1515/pp-2023-0033
BibTeX
@article{Canda2024,
author = {Canda, Aras Emre and Sever, Tolga and Calibasi Kocal, Gizem and Basbinar, Yasemin and Ellidokuz, Hulya},
title = {In vitro 3D microfluidic peritoneal metastatic colorectal cancer model for testing different oxaliplatin-based HIPEC regimens},
journal = {Pleura and Peritoneum},
year = {2024},
volume = {9},
number = {1},
pages = {23--29},
doi = {10.1515/pp-2023-0033}
}
EUVIMED